ECSP18013690A - Anticuerpos pd-l1 (ligando 1 de muerte celular programada) - Google Patents

Anticuerpos pd-l1 (ligando 1 de muerte celular programada)

Info

Publication number
ECSP18013690A
ECSP18013690A ECIEPI201813690A ECPI201813690A ECSP18013690A EC SP18013690 A ECSP18013690 A EC SP18013690A EC IEPI201813690 A ECIEPI201813690 A EC IEPI201813690A EC PI201813690 A ECPI201813690 A EC PI201813690A EC SP18013690 A ECSP18013690 A EC SP18013690A
Authority
EC
Ecuador
Prior art keywords
antibodies
link
cellular death
programmed cellular
programmed
Prior art date
Application number
ECIEPI201813690A
Other languages
English (en)
Inventor
Marshall Davenport Snavely
Juqun Shen
Vera Molkenthin
Dale Lincoln Ludwig
Yiwen Li
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP18013690A publication Critical patent/ECSP18013690A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen al ligando 1 de muerte celular programada 1 humana (PD-L1), y pueden ser útiles para tratar tumores hematológicos y sólidos solos y en combinación con quimioterapia y otros terapéuticos de cáncer.
ECIEPI201813690A 2015-08-24 2018-02-22 Anticuerpos pd-l1 (ligando 1 de muerte celular programada) ECSP18013690A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562209056P 2015-08-24 2015-08-24

Publications (1)

Publication Number Publication Date
ECSP18013690A true ECSP18013690A (es) 2018-04-30

Family

ID=56801855

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201813690A ECSP18013690A (es) 2015-08-24 2018-02-22 Anticuerpos pd-l1 (ligando 1 de muerte celular programada)

Country Status (25)

Country Link
US (2) US10214586B2 (es)
EP (1) EP3341020B1 (es)
JP (1) JP6518005B2 (es)
KR (1) KR20180030899A (es)
CN (1) CN107921131A (es)
AR (1) AR105654A1 (es)
AU (1) AU2016313404B2 (es)
BR (1) BR112018001506A2 (es)
CA (1) CA2994425C (es)
CL (1) CL2018000454A1 (es)
CO (1) CO2018002009A2 (es)
CR (1) CR20180048A (es)
DO (1) DOP2018000045A (es)
EA (1) EA201890278A1 (es)
EC (1) ECSP18013690A (es)
ES (1) ES2777603T3 (es)
HK (1) HK1249023A1 (es)
IL (1) IL256922A (es)
MX (1) MX2018002170A (es)
PE (1) PE20180604A1 (es)
PH (1) PH12018500394A1 (es)
SV (1) SV2018005640A (es)
TN (1) TN2018000044A1 (es)
TW (1) TW201718650A (es)
WO (1) WO2017034916A1 (es)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
US20180291107A1 (en) * 2015-11-24 2018-10-11 Eli Lilly And Company Combination therapy for cancer
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
JP6730466B2 (ja) 2016-06-13 2020-07-29 アイ−エムエービー バイオファーマ ユーエス リミテッド 抗ｐｄ−ｌ１抗体およびその使用
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
EP3497128A2 (en) 2016-08-09 2019-06-19 Kymab Limited Anti-icos antibodies
KR20240019398A (ko) 2016-10-28 2024-02-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018085555A1 (en) 2016-11-03 2018-05-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
WO2018102786A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for modulation of car-t cells
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
IL269026B2 (en) 2017-03-31 2024-12-01 Bristol Myers Squibb Co Anti-pd-1 antibodies for treating tumors in high tumor mutational burden (tmb) patients
JP2020515637A (ja) 2017-04-03 2020-05-28 オンコロジー、インコーポレイテッド 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
US20210340250A1 (en) 2017-05-30 2021-11-04 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
KR102713203B1 (ko) 2017-05-30 2024-10-10 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
KR20240155979A (ko) 2017-05-30 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
WO2018223040A1 (en) 2017-06-01 2018-12-06 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-pd-1 antibody
CN110891605A (zh) * 2017-06-07 2020-03-17 希沃尔拜克治疗公司 免疫调节化合物的抗体缀合物及其用途
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
CN111793060B (zh) 2017-07-14 2023-06-06 先天肿瘤免疫公司 Nlrp3调节剂
PE20200839A1 (es) 2017-08-01 2020-08-13 Lilly Co Eli Anticuerpos anti-cd137
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
PT3697810T (pt) 2017-10-18 2026-02-19 Alpine Immune Sciences Inc Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
SG11202003626RA (en) 2017-11-06 2020-05-28 Bristol Myers Squibb Co Methods of treating a tumor
AU2018387741B2 (en) * 2017-12-19 2025-09-25 Invox Pharma Limited FC binding fragments comprising a PD-L1 antigen-binding site
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
CN115925943A (zh) * 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
US20210363242A1 (en) 2018-01-16 2021-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
CN111629731A (zh) 2018-01-22 2020-09-04 百时美施贵宝公司 治疗癌症的组合物和方法
WO2019144126A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
US20210213041A1 (en) 2018-02-06 2021-07-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
TWI702954B (zh) 2018-03-01 2020-09-01 美商美國禮來大藥廠 Cd73抑制劑
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
JP7390301B2 (ja) 2018-03-23 2023-12-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ヒトｐｄ－ｌ２抗体およびその使用方法
CN112020517B (zh) 2018-03-23 2024-10-29 伊莱利利公司 用于与抗pd-l1抗体组合的抗cd137抗体
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
MA52212A (fr) 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
WO2019195452A1 (en) 2018-04-04 2019-10-10 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
JP7351850B2 (ja) 2018-04-25 2023-09-27 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３修飾因子
WO2019229616A1 (en) * 2018-05-28 2019-12-05 Orion Biotechnology Switzerland Sàrl Ccr5 inhibitor for use in treating cancer
EP3818085A4 (en) * 2018-06-01 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP2019208422A (ja) * 2018-06-04 2019-12-12 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途
CN120843603A (zh) 2018-07-11 2025-10-28 布里格姆妇女医院 用于跨血脑屏障递送试剂的方法和组合物
WO2020020307A1 (en) 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
SG11202100693UA (en) 2018-07-26 2021-02-25 Bristol Myers Squibb Co Lag-3 combination therapy for the treatment of cancer
TWI728400B (zh) 2018-07-26 2021-05-21 美商美國禮來大藥廠 Cd226促效劑抗體
WO2020037094A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
WO2020037091A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
KR102817037B1 (ko) 2018-08-16 2025-06-04 인네이트 튜머 이뮤니티, 인코포레이티드 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
EP3864046A1 (en) 2018-10-09 2021-08-18 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
CA3117016A1 (en) 2018-10-19 2020-04-23 Bristol-Myers Squibb Company Combination therapy for melanoma
US12479917B2 (en) 2018-10-23 2025-11-25 Bristol-Myers Squibb Company Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody
EP3880186B1 (en) 2018-11-14 2024-04-03 Regeneron Pharmaceuticals, Inc. Intralesional administration of pd-1 inhibitors for treating skin cancer
MY205758A (en) 2018-11-16 2024-11-12 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
JP7584418B2 (ja) 2018-12-04 2024-11-15 ブリストル－マイヤーズ スクイブ カンパニー 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
WO2020146196A1 (en) 2019-01-11 2020-07-16 Eli Lilly And Company Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer
JP7373571B2 (ja) 2019-01-14 2023-11-02 イネイト・テューマー・イミュニティ・インコーポレイテッド がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン
KR102865929B1 (ko) 2019-01-14 2025-09-29 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
CN113301962A (zh) 2019-01-14 2021-08-24 先天肿瘤免疫公司 用于治疗癌症的杂环nlrp3调节剂
JP7506080B2 (ja) 2019-01-14 2024-06-25 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３モジュレーター
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
SG11202108089SA (en) 2019-02-28 2021-08-30 Regeneron Pharma Administration of pd-1 inhibitors for treating skin cancer
SG11202109003QA (en) 2019-03-06 2021-09-29 Regeneron Pharma Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
CN113677402A (zh) 2019-03-28 2021-11-19 百时美施贵宝公司 治疗肿瘤的方法
CN113891748A (zh) 2019-03-28 2022-01-04 百时美施贵宝公司 治疗肿瘤的方法
US20200318200A1 (en) 2019-04-02 2020-10-08 The Brigham And Women's Hospital, Inc. Methods for Identifying Progression of a Primary Melanoma
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
CN114206926B (zh) 2019-06-10 2022-06-17 山东博安生物技术股份有限公司 抗PDL1和TGFβ的双功能融合蛋白及其用途
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021041319A1 (en) 2019-08-29 2021-03-04 Eli Lilly And Company Crystalline forms of a cd73 inhibitor
WO2021055994A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
EP4034248A1 (en) 2019-09-25 2022-08-03 Bristol-Myers Squibb Company Composite biomarker for cancer therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092071A1 (en) 2019-11-07 2021-05-14 Oncxerna Therapeutics, Inc. Classification of tumor microenvironments
CN115942973A (zh) 2019-11-08 2023-04-07 百时美施贵宝公司 用于黑色素瘤的lag-3拮抗剂疗法
US20220396619A1 (en) 2019-11-12 2022-12-15 Eli Lilly And Company Cd200 receptor antagonist binding molecules
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
JP2023510108A (ja) 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ
EP4087842A1 (en) 2020-01-10 2022-11-16 Innate Tumor Immunity, Inc. Nlrp3 modulators
CN115279400A (zh) 2020-01-10 2022-11-01 布里格姆妇女医院 用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物
US20230210988A1 (en) 2020-01-29 2023-07-06 Merus N.V. Means and method for modulating immune cell engaging effects
KR20220133996A (ko) 2020-01-30 2022-10-05 오엔에이 테라퓨틱스 에스.엘. 암 및 암 전이를 치료하기 위한 병용 요법
EP4100426A1 (en) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 and uses thereof
EP4110407A1 (en) 2020-02-28 2023-01-04 Bristol-Myers Squibb Company Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
JP2023516724A (ja) 2020-03-06 2023-04-20 オーエヌエー セラピューティクス エセ．エレ． 抗ｃｄ３６抗体及び癌を治療するためのそれらの使用
BR112022017637A2 (pt) 2020-03-06 2022-11-08 Celgene Quanticel Res Inc Métodos de tratamento do câncer de pulmão de células pequenas e/ou câncer de pulmão de células não pequenas
TW202202521A (zh) 2020-03-23 2022-01-16 美商必治妥美雅史谷比公司 用於治療癌症之抗ccr8抗體
KR20230015954A (ko) 2020-05-26 2023-01-31 리제너론 파마슈티칼스 인코포레이티드 Pd-1 억제제의 투여에 의한 자궁경부암의 치료 방법
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
IL300328A (en) 2020-08-26 2023-04-01 Regeneron Pharma Methods for treating cancer by administering a PD-1 inhibitor
EP4204095A1 (en) 2020-08-28 2023-07-05 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
JP2023542490A (ja) 2020-09-03 2023-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することによりがん疼痛を処置する方法
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
US20230364127A1 (en) 2020-10-06 2023-11-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
AU2021364837A1 (en) 2020-10-23 2023-05-25 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
KR20230098279A (ko) 2020-10-28 2023-07-03 이케나 온콜로지, 인코포레이티드 Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
MX2023011007A (es) 2021-03-23 2023-12-07 Regeneron Pharma Metodos para tratar el cancer en pacientes inmunosuprimidos o inmunocomprometidos mediante la administracion de un inhibidor de pd-1.
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
WO2022204438A1 (en) 2021-03-25 2022-09-29 Oncxerna Therapeutics, Inc. Targeted therapies in cancer
US20240181052A1 (en) 2021-03-29 2024-06-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
MX2024000406A (es) 2021-07-19 2024-04-18 Regeneron Pharma Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer.
JP2024529502A (ja) 2021-07-30 2024-08-06 オーエヌエー セラピューティクス エセ．エレ． 抗ｃｄ３６抗体及び癌を治療するためのそれらの使用
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN118176214A (zh) 2021-10-29 2024-06-11 百时美施贵宝公司 血液癌症的lag-3拮抗剂疗法
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
MX2024008831A (es) 2022-01-26 2024-07-25 Bristol Myers Squibb Co Terapia combinada para carcinoma hepatocelular.
CA3243885A1 (en) 2022-02-17 2023-08-24 Vyriad, Inc. COMBINATIONS OF CHECKPOINT INHIBITORS AND ONCOLYTIC VIRUS FOR CANCER TREATMENT
MX2024010310A (es) 2022-02-25 2024-08-28 Bristol Myers Squibb Co Terapia de combinacion para carcinoma colorrectal.
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
CA3254481A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag USE OF ANTI-CLAUDIN-1 ANTIBODIES TO INCREASE T LYMPHOCYTE AVAILABILITY
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
US20260042840A1 (en) 2022-04-07 2026-02-12 Bristol-Myers Squibb Company Methods of treating tumor
IL315992A (en) 2022-04-08 2024-11-01 Bristol Myers Squibb Co Identification, classification and quantification of tertiary lymphoid structures using machine learning
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
JP2025526369A (ja) 2022-07-27 2025-08-13 アストラゼネカ・アクチエボラーグ Ｐｄ－１／ｐｄ－ｌ１阻害剤を有するインターロイキン１２を発現する組換えウイルスの組み合わせ
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
JP2025533015A (ja) 2022-09-30 2025-10-03 アレンティス セラピューティクス アクチェンゲゼルシャフト 薬物抵抗性肝細胞癌の処置
EP4626446A1 (en) 2022-12-01 2025-10-08 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
IL321575A (en) 2022-12-21 2025-08-01 Bristol Myers Squibb Co Combination therapy for lung cancer
JP2026504180A (ja) 2023-01-30 2026-02-03 カイマブ・リミテッド 抗体
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
US20250114468A1 (en) 2023-10-09 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383424C (en) 1999-08-23 2011-02-15 Gordon Freeman Novel b7-4 molecules and uses therefor
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
ES2288900T3 (es) * 2001-10-05 2008-02-01 Affimed Therapeutics Ag Anticuerpo de origen humano para inhibir la agregacion de trombocitos.
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CA2473036A1 (en) * 2002-01-23 2003-07-31 Paul Leslie Ornstein Melanocortin receptor agonists
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
WO2006042237A2 (en) 2004-10-06 2006-04-20 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
JP5191537B2 (ja) * 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CN104736168B (zh) * 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
CN104936982B (zh) 2012-08-03 2020-04-24 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
EP3551659A1 (en) * 2016-12-08 2019-10-16 Eli Lilly and Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies

Also Published As

Publication number Publication date
CL2018000454A1 (es) 2018-08-03
HK1249023A1 (zh) 2018-10-26
ES2777603T3 (es) 2020-08-05
AU2016313404B2 (en) 2019-04-04
JP2018531219A (ja) 2018-10-25
EP3341020B1 (en) 2020-02-26
US10214586B2 (en) 2019-02-26
KR20180030899A (ko) 2018-03-26
EP3341020A1 (en) 2018-07-04
CA2994425C (en) 2020-04-28
CA2994425A1 (en) 2017-03-02
PH12018500394A1 (en) 2018-08-29
EA201890278A1 (ru) 2018-07-31
AR105654A1 (es) 2017-10-25
JP6518005B2 (ja) 2019-05-22
CN107921131A (zh) 2018-04-17
TW201718650A (zh) 2017-06-01
AU2016313404A1 (en) 2018-02-08
SV2018005640A (es) 2018-07-23
CR20180048A (es) 2018-03-20
US20190144544A1 (en) 2019-05-16
BR112018001506A2 (pt) 2018-09-18
MX2018002170A (es) 2018-04-24
WO2017034916A1 (en) 2017-03-02
CO2018002009A2 (es) 2018-05-10
US20170058033A1 (en) 2017-03-02
PE20180604A1 (es) 2018-04-09
DOP2018000045A (es) 2018-03-30
TN2018000044A1 (en) 2019-07-08
IL256922A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
ECSP18013690A (es) Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CO2019001646A2 (es) Anticuerpos de anti-tim-3
MY199019A (en) Pd-1 antibodies
ECSP20007663A (es) Anticuerpos anti-cd137
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX2020006668A (es) Anticuerpos para lilrb2.
JOP20200003B1 (ar) أجسام مضادة ثنائية النوعية مثبطة لنقاط مراقبة المناعة
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
CO2017010618A2 (es) Anticuerpos contra icos
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
BR112018013653A2 (pt) anticorpos anti-pd-1
MX2022005618A (es) Metodos para tratar cancer que expresa la proteina del ligando 1 de muerte celular programada (pd-l1).
MX2016003103A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para tratar tumores.
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
MA40074A (fr) Composés liant ras multivalents
TR201905458T4 (tr) Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri.
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
AR111193A1 (es) Anticuerpos biespecíficos que se unen con ligando 1 de muerte celular programada humana (pd-l1) y con la proteína 3 que contiene dominio de inmunoglobulina y mucina de células t (tim-3)
MX2018008964A (es) Biomarcadores para el tratamiento del cancer con apilimod.